Results 101 to 110 of about 1,514 (148)

Insuficiencia hepática aguda secundaria a fiebre amarilla: un escenario complejo. [PDF]

Clin Liver Dis (Hoboken), 2019
Song ATW, D'Albuquerque YLAC.
europepmc   +1 more source

[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]. [PDF]

Med Intensiva, 2021
Díaz E, Amézaga Menéndez R, Vidal Cortés P, Escapa MG, Suberviola B, Serrano Lázaro A, Marcos Neira P, Quintana Díaz M, Catalán González M.   +8 more
europepmc   +1 more source

Conocimientos básicos sobre enfermedades víricas emergentes: apuntes para atención primaria (parte 2). [PDF]

FMC, 2018
Alonso Saratxaga E, Pérez Esquerdo MR.
europepmc   +1 more source

Control of occult hepatitis B virus infection. [PDF]

Adv Lab Med, 2022
Lalana Garcés M, Ortiz Pastor O, Solé Enrech G, Guerra-Ruiz AR, Casals Mercadal G, Almería Lafuente A, Ballesteros Vizoso MA, Medina PG, Salgüero Fernández S, Zamora Trillo A, Aured de la Serna I, Hurtado JC, Pérez-Del-Pulgar S, Forns X, Morales Ruiz M.   +14 more
europepmc   +1 more source

HISTÓRIA NATURAL DA COVID-19 E SUAS RELAÇÕES TERAPÊUTICAS

, 2020
Meneses ASd.
europepmc   +1 more source

[Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2]. [PDF]

Rev Esp Quimioter, 2021
Reina J.
europepmc   +1 more source

Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. [PDF]

Eur J Hosp Pharm, 2020
Margusino-Framiñán L, Cid-Silva P, Rotea-Salvo S, Mena-de-Cea Á, Suárez-López F, Vázquez-Rodríguez P, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á.   +9 more
europepmc   +1 more source

COVID-19 and VIH. [PDF]

Colomb Med (Cali), 2020
Posada-Vergara MP, Alzate-Ángel JC, Martínez-Buitrago E.   +2 more
europepmc   +1 more source

Variability in public procurement prices for Group 1A drugs in the specialized pharmaceutical component: an observational study, 2013-2022. [PDF]

Epidemiol Serv Saude
Rossignoli P, Pontarolo R, Fernandez-Llimos F.   +2 more
europepmc   +1 more source